The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Overview of attention for article published in BMC Cancer, November 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

patent: 4 patents

Citations

dimensions_citation: 57 Dimensions

Readers on

mendeley: 49 Mendeley
citeulike: 1 CiteULike

Summary News Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

SUPPRESSION OF CANCER

Application EP-3241560-A1

European Patent Office

INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE…

Application EP-2519253-A4

European Patent Office

THERAPEUTIC FUSION PROTEINS

Application WO-2012156743-A1

World Intellectual Property Organisation (WIPO)

INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE…

Application EP-2519253-A2

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.